Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microgynon + empagliflozin
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Microgynon + empagliflozin is a combination of two pharmaceutical agents used concomitantly. Microgynon is an oral contraceptive containing ethinylestradiol and levonorgestrel, which act as synthetic estrogen and progestogen, respectively, to inhibit ovulation and prevent pregnancy. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the treatment of type 2 diabetes mellitus; it lowers blood glucose by promoting urinary glucose excretion via inhibition of renal SGLT2. Clinical studies have shown that co-administration of these drugs does not result in clinically significant pharmacokinetic interactions, and both are well tolerated when used together[1][5][6].
- Brand names
- Jardiance
- Other names
- ethinylestradiol + levonorgestrel (for Microgynon)SGLT2 inhibitor (for empagliflozin)
02
Targets
PR (Progesterone receptor)ESR2 (ERβ)SGLT2 (Sodium-glucose cotransporter protein subunit 2)ESR1 (ERα)
Beyond the preview
Go deeper on microgynon + empagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microgynon + empagliflozin.